Literature DB >> 9058215

Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays.

D J Murray1, W J Brosnahan, B Pennell, D Kapalanski, J M Weiler, J Olson.   

Abstract

OBJECTIVE: Laboratory and point-of-care coagulation tests are frequently obtained to determine the presence of heparin after surgical procedures. The objective of this study was (1) to compare the sensitivity of the activated coagulation time (ACT), activated partial thromboplastin time (aPTT), protamine titration (Hepcon; HMS Medtronic, Hemotec, Englewood, CO), and thromboelastography (TEG) with heparin anticoagulation and (2) to determine how frequently residual heparin is present in the 24-hour period after heparin neutralization in cardiopulmonary bypass (CPB) patients.
DESIGN: A prospective study.
SETTING: A tertiary care university teaching center that performs more than 15,000 surgical procedures per year. PARTICIPANTS: Vascular surgical (n = 17) and CPB (n = 29).
INTERVENTIONS: In vascular surgical patients, coagulation tests (ACT, protamine titration [Hepcon], and TEG) were obtained before and 90 minutes after heparin (50 to 60 U/kg IV) and compared with heparin concentration determined by factor Xa inhibition assay. In cardiac surgical patients, ACT and heparin concentrations were measured after anesthesia induction, during CPB, after protamine neutralization, and 3 as well as 6 hours after CPB. In addition to heparin concentrations and ACT measures, platelet counts, fibrinogen levels, and bleeding times were determined before and 3 and 24 hours after CPB.
MEASUREMENTS AND MAIN RESULTS: Ninety minutes after heparin, significant heparin concentrations were present in all vascular surgical patients, but ACT was elevated in only 4 of 17 patients. Protamine titration (Hepcon) correlated with the factor Xa inhibitory assay for heparin (r2 = 0.76). All 17 patients had an abnormal TEG (mean "R" time = 81 +/- 39 minutes) and a marked elevation of aPTT (135 +/- 35 sec [normal 22 to 33 seconds]) 90 minutes after heparin. In CPB patients, ACT did not correlate with heparin assays. After protamine neutralization of heparin in CPB patients, ACT returned to baseline despite the presence of heparin in 3 of 29 patients (0.22, 0.18, and 0.33 U/mL).
CONCLUSIONS: ACT was less sensitive to residual heparin anticoagulation than aPTT, TEG, and whole blood heparin assay. The whole blood heparin assay (Hepcon) provided sensitive and specific data about the presence of residual heparin. Despite the limitation of ACT in detecting heparin, the investigators found that residual heparin was not common in the period after uncomplicated CPB.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9058215     DOI: 10.1016/s1053-0770(97)90247-0

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  19 in total

1.  Relationship between the heparin management test and the HemoTec activated clotting time in patients undergoing percutaneous coronary intervention.

Authors:  S Tsimikas; R Beyer; A Hassankhani
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

Review 2.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

3.  Comparison of point-of-care activated clotting time systems utilized in a single pediatric institution.

Authors:  Jorge W Ojito; Robert L Hannan; Michelle Moore Burgos; Hyunsoo Lim; Monique Huynh; Evelio Velis; Marino Arocha; Christopher F Tirotta; Redmond P Burke
Journal:  J Extra Corpor Technol       Date:  2012-03

4.  A colorimetric heparin assay based on the inhibition of the oxidase mimicking activity of cerium oxide nanoparticles.

Authors:  Hong Liao; Yilin Liu; Min Chen; Min Wang; Hua Yuan; Lianzhe Hu
Journal:  Mikrochim Acta       Date:  2019-04-10       Impact factor: 5.833

Review 5.  Recent advances in biotechnology for heparin and heparan sulfate analysis.

Authors:  Meng Qiao; Lei Lin; Ke Xia; Jun Li; Xing Zhang; Robert J Linhardt
Journal:  Talanta       Date:  2020-06-14       Impact factor: 6.057

6.  The use of the activated clotting time for monitoring heparin therapy in critically ill patients.

Authors:  Jan J De Waele; Sebastiaan Van Cauwenberghe; Eric Hoste; Dominique Benoit; Francis Colardyn
Journal:  Intensive Care Med       Date:  2003-01-16       Impact factor: 17.440

7.  STS/SCA/AmSECT Clinical Practice Guidelines: Anticoagulation during Cardiopulmonary Bypass.

Authors:  Linda Shore-Lesserson; Robert A Baker; Victor Ferraris; Philip E Greilich; David Fitzgerald; Philip Roman; John Hammon
Journal:  J Extra Corpor Technol       Date:  2018-03

8.  A ratiometric fluorometric heparin assay based on the use of CdTe and polyethyleneimine-coated carbon quantum dots.

Authors:  Si-Si Liang; Xu Deng; Yao-Yao Fan; Jun Li; Man Wang; Zhi-Qi Zhang
Journal:  Mikrochim Acta       Date:  2018-10-25       Impact factor: 5.833

9.  Long-term extracorporeal circulation management: the role of low- and high-range heparin ACT tests.

Authors:  Daniel Herbst; Hani K Najm; Kumar Neerod Jha
Journal:  J Extra Corpor Technol       Date:  2008-12

10.  Accuracy of blood glucose measurements using the NOVA StatStrip® glucometer during cardiac surgery: a prospective observational study.

Authors:  Yosuke Nakadate; Hiroaki Sato; Patricia Roque; Tamaki Sato; Takashi Matsukawa; Linda Wykes; Akiko Kawakami; Thomas Schricker
Journal:  Can J Anaesth       Date:  2019-03-20       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.